8.78
price up icon0.69%   0.06
after-market Handel nachbörslich: 9.04 0.26 +2.96%
loading
Schlusskurs vom Vortag:
$8.72
Offen:
$8.41
24-Stunden-Volumen:
2.07M
Relative Volume:
1.67
Marktkapitalisierung:
$1.13B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-14.16
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
-8.73%
1M Leistung:
-6.00%
6M Leistung:
-37.02%
1J Leistung:
-40.64%
1-Tages-Spanne:
Value
$8.27
$9.14
1-Wochen-Bereich:
Value
$8.27
$9.66
52-Wochen-Spanne:
Value
$8.27
$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name
Firmenname
Neogenomics Inc
Name
Telefon
(239) 768-0600
Name
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Name
Mitarbeiter
2,200
Name
Twitter
@NeoGenomics
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
NEO's Discussions on Twitter

Vergleichen Sie NEO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
NEO
Neogenomics Inc
8.78 1.13B 628.25M -78.55M -29.73M -0.62
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
437.91 165.21B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
181.77 130.05B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
393.73 31.91B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
103.00 29.38B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 27.28B 15.41B 1.37B 2.11B 7.50

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-13 Herabstufung The Benchmark Company Buy → Hold
2024-12-10 Eingeleitet Jefferies Buy
2024-05-01 Fortgesetzt Craig Hallum Buy
2023-12-29 Bestätigt BTIG Research Buy
2023-08-21 Hochstufung Stephens Equal-Weight → Overweight
2023-05-16 Herabstufung Raymond James Outperform → Mkt Perform
2023-05-09 Hochstufung BTIG Research Neutral → Buy
2023-02-24 Hochstufung The Benchmark Company Hold → Buy
2023-02-01 Hochstufung Needham Hold → Buy
2022-08-26 Herabstufung The Benchmark Company Buy → Hold
2022-08-22 Herabstufung Needham Buy → Hold
2022-06-03 Eingeleitet Piper Sandler Overweight
2022-03-29 Herabstufung BofA Securities Buy → Neutral
2022-03-29 Herabstufung Stephens Overweight → Equal-Weight
2022-01-18 Fortgesetzt Stephens Overweight
2021-12-16 Eingeleitet Cowen Outperform
2021-11-05 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-10-14 Hochstufung Raymond James Mkt Perform → Outperform
2021-06-03 Eingeleitet Goldman Buy
2021-02-25 Fortgesetzt Needham Buy
2021-02-25 Herabstufung Raymond James Outperform → Mkt Perform
2021-01-28 Eingeleitet Truist Buy
2020-12-11 Fortgesetzt BTIG Research Buy
2020-10-28 Bestätigt Needham Buy
2020-09-09 Eingeleitet Morgan Stanley Overweight
2020-08-28 Eingeleitet Guggenheim Buy
2020-07-29 Bestätigt Needham Buy
2020-06-25 Eingeleitet BofA/Merrill Buy
2020-04-21 Fortgesetzt Stephens Overweight
2020-03-02 Fortgesetzt Craig Hallum Buy
2020-02-28 Hochstufung First Analysis Sec Outperform → Strong Buy
2020-01-23 Herabstufung First Analysis Sec Strong Buy → Outperform
2019-10-30 Bestätigt Needham Buy
2019-05-01 Bestätigt Needham Buy
2019-03-29 Bestätigt Needham Buy
2019-01-03 Eingeleitet Needham Buy
2018-10-24 Hochstufung First Analysis Sec Outperform → Strong Buy
2018-08-21 Eingeleitet Leerink Partners Outperform
2018-05-02 Herabstufung First Analysis Sec Overweight → Equal-Weight
2017-09-11 Herabstufung BTIG Research Buy → Neutral
2017-08-24 Eingeleitet Gabelli & Co Buy
2016-12-15 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Neogenomics Inc Aktie (NEO) Neueste Nachrichten

pulisher
Apr 03, 2025

NeoGenomics stock hits 52-week low at $8.9 amid challenges By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

NeoGenomics stock hits 52-week low at $8.9 amid challenges - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - Yahoo Finance

Apr 03, 2025
pulisher
Apr 02, 2025

NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

NeoGenomics Schedules its First Quarter Earnings Release for April 30, 2019 - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

NeoGenomics announces CEO transition - MSN

Apr 02, 2025
pulisher
Apr 01, 2025

New CEO assumes role at NeoGenomics - Gulfshore Business

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics appoints Tony Zook as CEO - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics, Inc. Announces CEO Changes - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - BioSpace

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics appoints Tony Zook as CEO By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics Appoints Tony Zook Chief Executive - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

NeoGenomics' New CEO Zook Takes Over as Smith Retires - MarketWatch

Apr 01, 2025
pulisher
Apr 01, 2025

Tony Zook Assumes Role As Chief Executive Officer Of Neogenomics - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Diagnostic Leader NeoGenomics Taps 30-Year Veteran to Drive Oncology Testing Growth - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Benchmark maintains Hold on Neogenomics stock, reiterates price target By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 22, 2025

Where are the Opportunities in (NEO) - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 21, 2025

3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Piper Sandler maintains Neogenomics stock with $18 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 19, 2025

NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

NeoGenomics Promotes Warren Stone to President & COO - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Fort Myers-based NeoGenomics names new COO - Gulfshore Business

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics elevates Warren Stone to President and COO - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard

Mar 18, 2025
pulisher
Mar 18, 2025

NeoGenomics Appoints Warren Stone As President & Chief Operating Officer -March 18, 2025 at 07:10 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

Commit To Buy NeoGenomics At $8, Earn 19.6% Annualized Using Options - Nasdaq

Mar 17, 2025
pulisher
Mar 15, 2025

NeoGenomics (NASDAQ:NEO) Stock Price Up 7.2%Here's What Happened - MarketBeat

Mar 15, 2025
pulisher
Mar 14, 2025

SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

NeoGenomics at Barclays Healthcare: Strategic Focus on Innovation - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Bank of New York Mellon Corp Purchases 15,269 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Average Target Price from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

(NEO) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 11, 2025
pulisher
Mar 11, 2025

NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Fort Myers-based NeoGenomics expands cancer testing reach with acquisition - News-Press

Mar 11, 2025
pulisher
Mar 11, 2025

Proficio Capital Partners LLC Invests $372,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

BTIG maintains $17 target on Neogenomics stock post-acquisition By Investing.com - Investing.com UK

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Acquires Pathline -March 10, 2025 at 08:13 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics expands with Pathline acquisition - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics expands with Pathline acquisition By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 08, 2025

NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St

Mar 08, 2025
pulisher
Mar 07, 2025

NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

NeoGenomics price target lowered to $17 from $18 at BTIG - MSN

Mar 07, 2025
pulisher
Mar 06, 2025

NeoGenomics at TD Cowen Conference: CEO Transition and Growth Plans By Investing.com - Investing.com UK

Mar 06, 2025

Finanzdaten der Neogenomics Inc-Aktie (NEO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$133.87
price down icon 3.49%
diagnostics_research DGX
$164.18
price down icon 3.78%
diagnostics_research LH
$225.00
price down icon 3.62%
diagnostics_research WAT
$324.92
price down icon 5.85%
diagnostics_research MTD
$1,022.66
price down icon 6.63%
diagnostics_research IQV
$154.73
price down icon 7.73%
Kapitalisierung:     |  Volumen (24h):